Parent Drug and Active Metabolite [Regulatives / Guidelines]

posted by joyjac – Philippines, 2006-05-09 09:45 (7355 d 20:24 ago) – Posting: # 120
Views: 15,104

FDA CDER Guidance states that if the parent drug can be measured, the confidence interval should be applied to the parent drug but data of the active metabolite must be submitted to provide evidence of comparable therapeutic outcome. Does this mean we need to calculate also the 90% CI for the active metabolite? What if the 90% CI for the parent drug falls within the BE limit but Not for the active metabolite? Highly appreciate your insight on this BE issue. Thanks.

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,570 registered users;
362 visitors (0 registered, 362 guests [including 17 identified bots]).
Forum time: 06:09 CEST (Europe/Vienna)

Most scientists today are devoid of ideas, full of fear, intent on
producing some paltry result so that they can add to the flood
of inane papers that now constitutes “scientific progress”
in many areas.    Paul Feyerabend

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5